Exelixis Eyes Zanza Launch as CABOMETYX Growth Faces NET Ramp Hurdle

Exelixis executives said they will continue expanding the CABOMETYX franchise while preparing for a potential launch of zanzalintinib (zanza) for colorectal cancer later this year. The update signals pipeline and commercial-expansion potential, though no clinical, regulatory, financial, or sales figures were disclosed.